Pyxis Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pyxis Oncology, Inc. on February 6, 2026, reporting events occurring on February 2, 2026. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
- CEO Departure: Dr. Lara Sullivan, M.D., ceased serving as Chief Executive Officer and principal executive officer effective February 2, 2026.
- Interim CEO Appointment: Tom Civik, a current director, was appointed as Interim Chief Executive Officer and principal executive officer effective February 2, 2026.
- Compensation Structure: Mr. Civik's employment agreement includes an annualized base salary of $710,000 and a target bonus of 60% of the base salary, prorated and contingent on Board-established objectives.
- Equity Grants:
- Initial Stock Option Grant: Options representing 1.1% of outstanding common stock, vesting in 12 equal monthly installments during the interim term.
- Top-up Grant: Options representing 0.4% of outstanding common stock, fully vested upon completion of a successful financing or strategic transaction during the interim term or within six months thereafter.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or operational outlook. The primary contingency noted is the vesting of the "Top-up Grant," which is contingent upon the successful completion of a financing or strategic transaction. The interim term will continue until the appointment of a permanent CEO or termination of the agreement.
Investor Verification Checklist
- Verify the exact number of shares underlying the 1.1% Initial Stock Option Grant and 0.4% Top-up Grant based on the share count as of February 2, 2026.
- Review the specific performance objectives established by the Board for Mr. Civik's target bonus.
- Monitor for the filing of the complete Civik employment agreement as an exhibit to the Form 10-K for the fiscal year ended December 31, 2025.
- Track the timeline for the appointment of a permanent Chief Executive Officer.